Investment
Features
FeesSafety
Academy
More
Pluang+

Nuveen Multi-Asset Income Fund trades at 8.13% discount with 10.18% yield but has risks from leverage and income coverage.

Market News
09 Oct 2026
Seeking Alpha
View Source
Neutral
Nuveen Multi-Asset Income Fund trades at 8.13% discount with 10.18% yield but has risks from leverage and income coverage.

The Nuveen Multi-Asset Income Fund (NMAI) offers a diversified mix of equity and fixed-income investments and currently trades at an 8.13% discount to its net asset value. It provides an attractive 10.18% distribution yield, but the payout is partly supported by capital gains rather than net investment income, raising sustainability concerns. Additionally, the fund's leverage of nearly 30% and sensitivity to rising short-term interest rates increase its risk and volatility, making it less suitable for conservative investors. Despite muted recent returns, NMAI's actively managed, diversified portfolio and discount to NAV may offer a moderately appealing long-term investment opportunity.

Nuveen Multi-Asset Income Fund (NMAI) is the story's subject. For readers following US stocks on Pluang, here is the market snapshot as of Oct 09, 2026 22:41 WIB: Out of 150 priced US stocks, 101 rose and 49 fell. Notable movers include TME at USD 8.40 with a 1-day change of +5.53% and 100% sell order activity, COIN at USD 181.37 with +5.45% and 76% buy order activity, and GME at USD 26.53 with +4.94% and 60% sell order activity.

More News

Sigenergy debuts AI-powered energy solutions and new partnerships at Malaysia's IGEM 2026.

Sigenergy debuts AI-powered energy solutions and new partnerships at Malaysia's IGEM 2026.

At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...

Market News
Bullish
3 hours ago
Entrada Therapeutics rated Buy with $8.50 target, expects higher drug dosing results in 2027.

Entrada Therapeutics rated Buy with $8.50 target, expects higher drug dosing results in 2027.

Entrada Therapeutics is rated Buy with a fair value of $8.50, implying about 52% upside from the current $5.61 price. The company’s Duchenne muscular dystrophy drug ENTR-601-44 showed a disappointing initial increase in dystrophin, but this is attrib...

Analyst Insights
Neutral
4 hours ago
Ten-year Treasury yields hit 5.36% amid systemic debt concerns and strong stock market gains.

Ten-year Treasury yields hit 5.36% amid systemic debt concerns and strong stock market gains.

Ten-year U.S. Treasury yields reached 5.36% intraday, reflecting growing systemic sovereign debt issues. Despite these concerns, the stock market showed strength with the S&P 500 rising 1.2% and the Dow gaining 0.9%, supported by a 43-week expansion ...

Market News
Neutral
4 hours ago
Pump.fun's token buyback drops as daily revenue falls 16%, impacting price support until April 2027.

Pump.fun's token buyback drops as daily revenue falls 16%, impacting price support until April 2027.

Pump.fun's daily revenue, which funds half of its token buyback and burn program, fell 16% from $1.89 million on October 5 to $1.59 million on October 9, causing the token price to drop 16.8% from its weekly high. The buyback program, running until A...

Protocol Fundamentals
Bearish
4 hours ago
Alphamin Resources offers a promising buy with stable tin mines and growth potential in DRC.

Alphamin Resources offers a promising buy with stable tin mines and growth potential in DRC.

Alphamin Resources Corp. operates two profitable tin mines in the Democratic Republic of Congo and is focusing on exploration around its Bisie resource, offering speculative growth potential. The company's current operations are stable and profitable...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App